The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2

Immunology and Cell Biology

Volumn 93, Issue 1, 2015, Pages 57-66

  Gil, Lázaro ^a   Marcos, Ernesto ^a   Izquierdo, Alienys ^b   Lazo, Laura ^a   Valdés, Iris ^a   Ambala, Peris ^c   Ochola, Lucy ^c   Hitler, Rikoi ^c   Suzarte, Edith ^a   Álvarez, Mayling ^b   Kimiti, Prisilla ^c   Ndung'U, James ^c   Kariuki, Thomas ^c   Guzmán, Mariá Guadalupe ^b   Guillén, Gerardo ^a   Hermida, Lisset ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^c INSTITUTE OF PRIMATE RESEARCH   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CHIMERIC PROTEIN; CHIMERIC PROTEIN DIIIC 2; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; NEUTRALIZING ANTIBODY; OLIGODEOXYNUCLEOTIDE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; ALUMINUM SULFATE; CAPSID PROTEIN; DENGUE VACCINE; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; PROTEIN BINDING; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENGUE; DENGUE VIRUS 2; HAPLORHINI; HUMORAL IMMUNITY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PROTEIN AGGREGATION; SERODIAGNOSIS; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; CHEMISTRY; CHLOROCEBUS AETHIOPS; DENGUE VIRUS; DRUG EFFECTS; FEMALE; FLOCCULATION; GENE EXPRESSION; GENETICS; IMMUNIZATION; IMMUNOLOGY; VIROLOGY;

ANIMALIA; DENGUE VIRUS; DENGUE VIRUS TYPE 2; MIRIDAE; MUS; PRIMATES;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CERCOPITHECUS AETHIOPS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; FEMALE; FLOCCULATION; GENE EXPRESSION; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; OLIGODEOXYRIBONUCLEOTIDES; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; VIRAL ENVELOPE PROTEINS;

EID: 84920549082     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2014.63     Document Type: Article

References (44)

1. Suaya JA, Shepard DS, Siqueira JB, Martelli CT, Lum LC, Tan LH et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg 2009; 80: 846-855.
2. Guzman A, Isturiz RE. Update on the global spread of dengue. Int J Antimicrob Agents 2010; 36(Suppl 1): S40-S42.
3. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 1984; 120: 653-669.
4. Guzman MG, Alvarez M, Rodriguez R, Rosario D, Vazquez S, Vald s L et al. Fatal dengue hemorrhagic fever in Cuba, 1997. Int J Infect Dis 1999; 3: 130-135.
5. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirusnaive adults. J Infect Dis 2010; 201: 370-377.
6. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380: 1559-1567.
7. Marcos E, Gil L, Lazo L, Izquierdo A, Brown E, Suzarte E et al. Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus. Arch Virol 2013; 158: 225-230.
8. Valdes I, Bernardo L, Gil L, Pavon A, Lazo L, Lopez C et al. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 2009; 394: 249-258.
9. Chaung HC. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy. Int Immunopharmacol 2006; 6: 1586-1596.
10. Bernardo L, Pavon A, Hermida L, Gil L, Valdes I, Cabezas S et al. The two component adjuvant IC31((R)) potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice. Vaccine 2011; 29: 4256-4263.
11. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol 2001; 166: 2372-2377.
12. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001; 31: 2154-2163.
13. Valdes I, Hermida L, Martin J, Menendez T, Gil L, Lazo L et al. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64kdomain III of dengue 2 and two components of Neisseria meningitidis. Vaccine 2009; 27: 995-1001.
14. Bernardo L, Fleitas O, Pavon A, Hermida L, Guillen G, Guzman MG. Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes. Clin Vaccine Immunol 2009; 16: 1829-1831.
15. Bernardo L, Izquierdo A, Prado I, Rosario D, Alvarez M, Santana E et al. Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2. Clin Vaccine Immunol 2008; 15: 439-446.
16. Wahala WM, Kraus AA, Haymore LB, ccavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody. Virology 2009; 392: 103-113.
17. Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, Flanagan A et al. An in-depth analysis of original antigenic sin in dengue virus infection. J Virol 2011; 85: 410-421.
18. Wahala WM, Huang C, Butrapet S, White LJ, de Silva AM. Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera. J Virol 2012; 86: 4019-4023.
19. Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 2012; 249: 12-20.
20. White LJ, Sariol CA, Mattocks MD, Wahala WM, Yingsiwaphat V, Collier ML et al. An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in Maccaques that differs qualitatively from immunity induced by live virus infection. J Virol 2013; 87: 3409-3424.
21. Valdes I, Hermida L, Gil L, Lazo L, Castro J, Martin J et al. Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use. Int J Infect Dis 2010; 14: e377-e383.
22. Valdes I, Gil L, Romero Y, Castro J, Puente P, Lazo L et al. The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2. Clin Vaccine Immunol 2011; 18: 455-459.
23. Izquierdo A, Valdes I, Gil L, Hermida L, Gutierrez S, Garcia A et al. Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2. Antiviral Res 2012; 95: 1-8.
24. Gil L, Bernardo L, Pavon A, Izquierdo A, Valdes I, Lazo L et al. Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cellmediated immunity in mice. J Gen Virol 2012; 93: 1204-1214.
25. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, Harris E. Interferondependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T-and B-cell-dependent immunity are less critical. J Virol 2004; 78: 2701-2710.
26. Dejnirattisai W, Duangchinda T, Lin CL, Vasanawathana S, Jones M, Jacobs M et al. A complex interplay among virus, dendritic cells, T cells, and cytokines in dengue virus infections. J Immunol 2008; 181: 5865-5874.
27. Gunther VJ, Putnak R, Eckels KH, Mammen MP, Scherer JM, Lyons A et al. A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine 2011; 29: 3895-3904.
28. Hatch S, Endy TP, Thomas S, Mathew A, Potts J, Pazoles P et al. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis 2011; 203: 1282-1291.
29. Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 2006; 24: 3165-3171.
30. Bernardo L, Izquierdo A, Alvarez M, Rosario D, Prado I, Lopez C et al. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res 2008; 80: 194-199.
31. Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE et al. Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010; 28: 2705-2715.
32. Robert PJ, Coller BA, Voss G, Vaughn DW, Clements D, Peters I et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005; 23: 4442-4452.
33. Moi ML, Takasaki T, Kurane I. Efficacy of tetravalent dengue vaccine in Thai schoolchildren. Lancet 2013; 30: 1094.
34. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004; 78: 4761-4775.
35. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 2002; 298: 146-159.
36. Simmons M, Burgess T, Lynch J, Putnak R. Protection against dengue virus by nonreplicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 2010; 396: 280-288.
37. Alvarez M, Rodriguez-Roche R, Bernardo L, Morier L, Guzman MG. Improved dengue virus plaque formation on BHK21 and LLCMK2 cells: evaluation of some factors. Dengue Bull 2005; 29: 49-57.
38. Clarke DH, Casals J. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg 1958; 7: 561-573.
39. Guzman MG, Deubel V, Pelegrino JL, Rosario D, Marrero M, Sariol C et al. Partial nucleotide and amino acid sequences of the envelope and the envelope/nonstructural protein-1 gene junction of four dengue-2 virus strains isolated during the 1981 Cuban epidemic. Am J Trop Med Hyg 1995; 52: 241-246.
40. Halstead SB, Marchette NJ. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am J Trop Med Hyg 2003; 69: 5-11.
41. Deubel V, Kinney RM, Trent DW. Nucleotide sequence and deduced amino acid sequence of the nonstructural proteins of dengue type 2 virus, Jamaica genotype: comparative analysis of the full-length genome. Virology 1988; 165: 234-244.
42. Lopez C, Gil L, Lazo L, Menendez I, Marcos E, Sanchez J et al. In vitro assembly of nucleocapsid-like particles from purified recombinant capsid protein of dengue-2 virus. Arch Virol 2009; 154: 695-698.
43. Gil L, Lopez C, Blanco A, Lazo L, Martin J, Valdes I et al. The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol 2009; 22: 23-30.
44. Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 1985; 22: 250-254.